Workman P - Search Results

1

HER3 Is an Actionable Target in Advanced Prostate Cancer.

Gil V, Miranda S, Riisnaes R, Gurel B, D'Ambrosio M, Vasciaveo A, Crespo M, Ferreira A, Brina D, Troiani M, Sharp A, Sheehan B, Christova R, Seed G, Figueiredo I, Lambros M, Dolling D, Rekowski J, Alajati A, Clarke M, Pereira R, Flohr P, Fowler G, Boysen G, Sumanasuriya S, Bianchini D, Rescigno P, Aversa C, Tunariu N, Guo C, Paschalis A, Bertan C, Buroni L, Ning J, Carreira S, Workman P, Swain A, Califano A, Shen MM, Alimonti A, Neeb A, Welti J, Yuan W, de Bono J; PCF/SU2C International Prostate Cancer Dream Team. Gil V, et al. Among authors: workman p. Cancer Res. 2021 Dec 15;81(24):6207-6218. doi: 10.1158/0008-5472.CAN-21-3360. Epub 2021 Nov 9. Cancer Res. 2021. PMID: 34753775 Free PMC article.

2

Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions.

Hoban PR, Walton MI, Robson CN, Godden J, Stratford IJ, Workman P, Harris AL, Hickson ID. Hoban PR, et al. Among authors: workman p. Cancer Res. 1990 Aug 1;50(15):4692-7. Cancer Res. 1990. PMID: 2114946

3

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Hostein I, et al. Among authors: workman p. Cancer Res. 2001 May 15;61(10):4003-9. Cancer Res. 2001. PMID: 11358818

4

Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowsett M, Workman P, Johnston SR. Kelland LR, et al. Among authors: workman p. Clin Cancer Res. 2001 Nov;7(11):3544-50. Clin Cancer Res. 2001. PMID: 11705875

5

Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling.

Clarke PA, George ML, Easdale S, Cunningham D, Swift RI, Hill ME, Tait DM, Workman P. Clarke PA, et al. Among authors: workman p. Cancer Res. 2003 Oct 15;63(20):6855-63. Cancer Res. 2003. PMID: 14583483

6

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.

Whittaker SR, Walton MI, Garrett MD, Workman P. Whittaker SR, et al. Among authors: workman p. Cancer Res. 2004 Jan 1;64(1):262-72. doi: 10.1158/0008-5472.can-03-0110. Cancer Res. 2004. PMID: 14729633

7

Clinical anticancer drug development: targeting the cyclin-dependent kinases.

Benson C, Kaye S, Workman P, Garrett M, Walton M, de Bono J. Benson C, et al. Among authors: workman p. Br J Cancer. 2005 Jan 17;92(1):7-12. doi: 10.1038/sj.bjc.6602229. Br J Cancer. 2005. PMID: 15558073 Free PMC article. Review.

8

Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition.

Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen SM. Beloueche-Babari M, et al. Among authors: workman p. Cancer Res. 2005 Apr 15;65(8):3356-63. doi: 10.1158/10.1158/0008-5472.CAN-03-2981. Cancer Res. 2005. PMID: 15833869

9

Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors.

Chau NM, Rogers P, Aherne W, Carroll V, Collins I, McDonald E, Workman P, Ashcroft M. Chau NM, et al. Among authors: workman p. Cancer Res. 2005 Jun 1;65(11):4918-28. doi: 10.1158/0008-5472.CAN-04-4453. Cancer Res. 2005. PMID: 15930314

10

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, Workman P. Raynaud FI, et al. Among authors: workman p. Clin Cancer Res. 2005 Jul 1;11(13):4875-87. doi: 10.1158/1078-0432.CCR-04-2264. Clin Cancer Res. 2005. PMID: 16000586

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

603 results

Search Page